SciSparc Ltd., a company focused on pharmaceutical preparations, has announced a significant financial move. On November 3, 2026, the company entered into a Securities Purchase Agreement (SPA) with an institutional investor, allowing it to issue convertible promissory notes totaling up to $10 million. This strategic decision is expected to enhance the company’s working capital and support its general corporate purposes.

The SPA allows SciSparc to issue notes in an initial amount of $3 million, which it sold for $2.55 million. The company plans to utilize the proceeds from this sale to strengthen its financial position. This move comes at a time when many companies in the pharmaceutical preparations sector are exploring various funding options to sustain operations and drive growth.

Background on SciSparc Ltd.

SciSparc Ltd. operates in the pharmaceutical preparations industry, classified under SIC code 2834. The company is listed on the Nasdaq under the ticker SPRC. As a non-accelerated filer, SciSparc has been active in the capital markets, with multiple recent filings indicating a focus on securing funding and enhancing its operational capabilities.

What the Filing Says

According to the SEC filing (accession number 0001213900-26-115602), the company has structured the issuance of convertible promissory notes to provide flexibility in its financing strategy. The filing states, "The Company intends to use the net proceeds from the sale of the Notes and any additional net proceeds from the exercise of the Warrants for working capital and general corporate purposes." This indicates a clear intention to bolster its operational capabilities through improved liquidity.

Impact of the Financing

The financing arrangement may significantly impact various stakeholders, including shareholders and potential investors. By securing up to $10 million, SciSparc aims to enhance its financial stability, which could lead to increased investor confidence. Additionally, the terms of the notes allow the company to request further investments, contingent on trading volume, which may attract additional interest from institutional investors.

What's Next for SciSparc Ltd.?

The filing does not specify immediate next steps beyond the initial issuance of the notes. However, it is clear that the company will be monitoring its trading volume closely to potentially access additional funding through the SPA. This strategic financing could position SciSparc favorably in the competitive pharmaceutical preparations market.